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Objective: We sought to characterize a novel cohort of patients with lung disease, anti-cyclic
citrullinated peptide (CCP) antibody positivity, without rheumatoid arthritis (RA) or other
connective tissue disease (CTD).
Methods: The study sample included 74 subjects with respiratory symptoms, evaluated
January 2008eJanuary 2010 and found to have a positive anti-CCP antibody but no evidence
for RA or other CTD. Each underwent serologic testing, pulmonary physiology testing, and
thoracic high-resolution computed tomography (HRCT) scan as part of routine clinical evalua-
tion.
Results: The majority of subjects were women, and most were former cigarette smokers. Four
distinct radiographic phenotypes were identified: isolated airways disease (54%), isolated
interstitial lung disease (ILD) (14%), mixed airways disease and ILD (26%), and combined pulmo-
nary fibrosis with emphysema (7%). This cohort had a predominance of airways disease, either
in isolation or along with a usual interstitial pneumonia-pattern of ILD. Among subjects with
high-titer anti-CCP positivity (nZ 33), three developed the articular manifestations of RA
during a median follow-up of 449 days.
Conclusion: We have described a unique cohort of patients with anti-CCP antibody positivity
and lung disease in the absence of existing RA or other CTD. The lung phenotypic characteris-
tics of this cohort resemble those of established RA and a few of these patients have developed3 398 1703; fax: þ1 303 398 1040.
.org (A. Fischer).
2 Elsevier Ltd. All rights reserved.
Lung disease and anti-CCP antibodies 1041articular RA within a short period of follow-up. The implications of a positive anti-CCP antibody
among patients with lung disease but not RA are not yet known, but we believe requires
further investigation.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Connective tissue diseases (CTDs) are often associated with
lung disease,1 and as a result, pulmonologists frequently
undertake screening for CTDs as a component of their
evaluation of patients presenting with respiratory symp-
toms of unknown cause; however, there is no standardized
approach to the assessment for CTD. Anti-cyclic citrulli-
nated peptide (CCP) antibodies, often a component of such
an assessment, are highly specific for rheumatoid arthritis
(RA) and are identified in majority of patients with RA.2
Anti-CCP positivity can predate the development of clini-
cally apparent joint inflammation in patients ultimately
diagnosed with RA.3,4 Likewise, lung disorders, particularly
interstitial lung disease (ILD) or certain airways diseases
(e.g., bronchiolitis or bronchiectasis), are common in
patients with RA and may also predate the articular mani-
festations of RA.5
Data on whether there is an association between anti-
CCP positivity and lung disease among patients with RA are
extremely limited and conflicting. In one study, there was
no difference in serum levels of anti-CCP antibodies
between RA patients with or without lung disease.6 In
another study, investigators found that high anti-CCP anti-
body levels were associated with RA-related lung disease.7
Far less well studied is the question of whether there is
a relationship between anti-CCP positivity and lung disease
in patients without RA (clinically apparent synovial
disease). We and others have proposed that anti-CCP is
a useful auto-antibody to assess in a patient presenting
with an idiopathic interstitial pneumonia, because the
presence of anti-CCP identifies ILD patients at risk for
developing RA.8,9 For those patients who do, the pulmonary
diagnosis changes from idiopathic ILD to RA-related ILD,
and with that comes arguably a change in management
strategies and prognosis.10 Primarily for research purposes,
we have proposed to identify ILD patients with anti-CCP as
having a “lung-dominant” form of connective tissue disease
(CTD),8 even in the absence of clinically apparent inflam-
matory joint disease.
In the current study, our goal was to characterize a novel
cohort of patients who presented with lung disease in the
absence of RA or other CTD and were found to have
a positive anti-CCP antibody on serologic screening. We
hypothesized that the lung manifestations in such patients
would resemble those found in RA-related lung disease e in
particular, airways or fibrosing ILD or pleural disease.
Furthermore, we hypothesized that some of our patients,
despite a limited study duration, would go on to develop
articular RA, suggesting that in some cases, lung disease
with a positive anti-CCP antibody may represent a forme
fruste presentation of RA.Methods
Cohort development
The cohort in this retrospective study was comprised of
patients who presented to our center between January
2008 and January 2010 for evaluation of unexplained
respiratory symptoms and who met the following inclusion
criteria: (1) age >18 years; (2) anti-CCP 20 international
units (IU) in our laboratory; (3) absence of RA or other CTD;
(4) absence of a history of (or currently present) joint
symptoms or signs suggestive of inflammatory arthritis; (5)
clinical evidence of lung disease (respiratory symptoms or
pulmonary physiologic, gas exchange, or chest imaging
abnormalities); and (6) thoracic high-resolution computed
tomography (HRCT) scan available for review. Each subject
underwent pulmonary physiology testing [based on current
accepted methodology11e13 and with results expressed as
a percentage of the predicted value for age, gender, and
height], and thoracic HRCT as part of their routine clinical
evaluation. This study was approved by the National Jewish
Health Institutional Review Board (IRB) (protocol HS #2454)
and due to the retrospective nature of the study; the
requirement for informed consent was waived.
Autoantibody testing
Pulmonologists at our center typically order a broad panel of
autoantibodies to screen forCTD inpatientswithunexplained
respiratory problems. In this study, the decision to check for
autoantibodies e including the anti-CCP antibody e was
made by the evaluating pulmonologist.
Anti-CCP testing
Anti-CCP was tested using the INOVA Diagnostics QUANTA
Lite CCP3.1 IgG/IgA ELISA kit (San Diego, CA, USA)
wherein a positive result is defined by an anti-CCP titer of
>20 IU. A positive result with this kit is defined by an anti-
CCP titer of >20 IU. A low-positive titer is defined as
21e39 IU, a moderate-positive titer as 40e59 IU, and
a high-titer positive as 60 IU.
Radiographic and histopathological data analyses
The thoracic HRCT scan for each subject was reviewed and
scored in a standardized manner by expert thoracic radi-
ologists (DAL, DAB, ISP) blinded to clinical data. The HRCT
scan was considered as demonstrating “airways disease” if
there was evidence of mosaic attenuation on inspiratory
images, air-trapping on expiratory images, cylindrical
1042 A. Fischer et al.bronchiectasis, or bronchiolitis (centrilobular nodularity).
The HRCT scan was considered as demonstrating “ILD” if
there was evidence of reticular and/or ground-glass opac-
ities, with or without traction bronchiectasis or honey-
combing, in a pattern consistent with diffuse parenchymal
lung disease. Available lung histopathologic specimens
were reviewed and scored in a standardized manner by
expert lung pathologists (RDAD, SDG) blinded to clinical
data.
Statistical analysis
Baseline data were tabulated using proportions, counts, or
medians with measures of central tendency. We compared
anti-CCP titer between subgroups defined by HRCT pattern
by using the KruskaleWallis Test (non-parametric equiva-
lent to one-way analysis of variance) and between former
and never smokers by using the ManneWhitney U test. We
compared HRCT patterns between subgroups stratified on
anti-CCP titer (low vs. non-low) by using the Chi-square
statistic. We used Spearman’s rank correlation to examine
the relationships between anti-CCP titer and other contin-
uous variables. We considered p< 0.05 to represent
statistical significance. All statistics were run using SAS,
Version 9.2 (SAS Inc.; Cary, NC).
Results
We identified 74 subjects who met our inclusion criteria.
The majority were women, and most were former cigarette
smokers (Table 1). Each subject presented withTable 1 Characteristics of subjects after stratification on
anti-CCP titer.
Low-titer
anti-CCP
(nZ 28)
Moderate-high
titer anti-CCP
(nZ 46)
Median age (range) 67 (20e85) 68 (36e84)
Female gender 18 (64%) 27 (59%)
History of cigarette
smoking
16 (57%) 27 (59%)
Current cigarette
smokers
3 (11%) 0
First degree relative
with RA
3 (11%) 7 (15%)
RF positive 6 (21%) 16 (35%)
Median RF (range) 138 (25e1580) 148 (31e3650)
ANA 1:320 0 4 (9%)
Median anti-CCP (range) 24 (21e37) 100 (40e235)
Isolated airways disease 17 (61%) 23 (50%)
Isolated ILD 5 (18%) 5 (11%)
Airways disease and ILD 5 (18%) 14 (30%)
Combined pulmonary
fibrosis with
emphysema
1 (4%) 4 (1%)
ANAZ anti-nuclear antibody, CCPZ cyclic citrullinated
peptide, RFZ rheumatoid factor, and ILDZ interstitial lung
disease.unexplained respiratory symptoms (dyspnea nZ 15 [20%],
cough nZ 17 [23%], or both nZ 42 [57%]). Based on
a comprehensive symptom review and clinical assessment
by the treating physician, no subject had a history of or
current symptoms or signs of joint inflammation (or non-
articular symptoms or signs of RA or other CTD). Nearly
half (nZ 36) of the subjects had rheumatologic evaluation
within the context of the positive anti-CCP and none of
these subjects had features to suggest RA or other CTD. The
remainder of the cohort (nZ 38) did not have specific
consultation with a rheumatologist, but on medical record
review, none had features to suggest RA or other CTD as
determined by their treating physician.
Twenty-eight (38%) subjects had a low-titer anti-CCP
(median 24 IU, range 21e37), 13 (18%) had a moderate-titer
anti-CCP (median 47 IU, range 40e58) and 33 (45%) had
a high-titer anti-CCP (median 124 IU, range 60e235).
Twenty-two (30%) subjects had an elevated rheumatoid
factor (RF) antibody (median 148 IU, range 25e3650), and
four (5%) subjects had a positive anti-nuclear antibody
(ANA) of >1:320 titer. No other auto-antibodies were
identified.HRCT patterns
Four distinct radiographic phenotypes were identified
(Tables 2e4): isolated airways disease, isolated ILD, mixed
airways disease and ILD, and combined pulmonary fibrosis
with emphysema (CPFE).14 Isolated airways disease was the
most common pattern identified (nZ 40, 54%). Twenty-one
subjects (28%) had a HRCT pattern consistent with oblit-
erative bronchiolitis; 11 (15%) with cellular bronchiolitis;
and 26 (35%) with cylindrical bronchiectasis. Among the 29
subjects with ILD, 19 had a HRCT scan pattern consistent
with an underlying histologic pattern of UIP.Histopathology findings
Ten subjects had endobronchial (nZ 6) or transbronchial
(nZ 4) biopsy specimens for review. All but one of the
subjects had evidence of airway inflammation; four had
evidence of lymphoplasmacytic or eosinophilic inflamma-
tion in the airways (Table 5 and Fig. 1). Fourteen subjects
had surgical lung biopsy specimens available for review: UIP
was the predominant pattern among those with ILD (7 of 11
cases) (Table 6 and Fig. 2). There was one case each with
non-specific interstitial pneumonia (NSIP), diffuse alveolar
damage, organizing pneumonia, and desquamative inter-
stitial pneumonia. In each of the ILD cases, along with the
primary histologic pattern, the pathologist identified areas
of interstitial lymphoplasmacytic inflammation (Fig. 2). The
three biopsy specimens from subjects whose HRCT scans
were categorized as having isolated airways disease all
showed evidence of airways inflammation. Seventeen
subjects underwent bronchoalveolar lavage (BAL): median
(interquartile range) number of cells per microliter for
macrophages was 80 (23e86), neutrophils was 6 (1e31),
lymphocytes was 8 (3e14), and eosinophils was 1 (0e1).
Table 2 Subgroup characteristics after stratification on HRCT pattern.
Age Female gender Smoking history RF positive Median anti-CCP titer
Isolated airways disease (nZ 40) 67 (36e85) 28 (70%) 19 (48%) 15 (38%) 44 IU (21e235)
Isolated ILD (nZ 10) 66 (63e78) 3 (30%) 7 (70%) 2 (20%) 54 IU (22e103)
Airways disease and ILD (nZ 19) 69 (53e84) 12 (63%) 12 (63%) 3 (16%) 81 IU (21e219)
Combined pulmonary fibrosis with
emphysema (nZ 5)
75 (66e84) 2 (40%) 5 (100%) 2 (40%) 81 IU (24e217)
ILDZ interstitial lung disease, HRCTZ high resolution computed tomography, RFZ rheumatoid factor, and CCPZ cyclic citrullinated
peptide.
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disease
There was no difference in anti-CCP titer between subjects
stratified on HRCT pattern (pZ 0.5), nor between never
and former smokers (pZ 0.8). Similarly, the clinical
features and types of lung disease identified were no
different between subgroups stratified on anti-CCP titer
(pZ 0.4). Anti-CCP titer did not correlate with any
measure of pulmonary physiology.Evolution to RA
None of the subjects with low- or moderate-titer anti-CCP
developed articular RA during the study period. Three (9%)
of the 33 subjects with high-titer anti-CCP developed the
articular manifestations of RA during a median follow-up
period of 449 days (interquartile range 328e579 days)
(Table 7). Only one of the three ever smoked; he was a 70-
year-old man with an anti-CCP titer of 175 IU and a RF titer
of 366 IU assessed w1 year prior to onset of symptoms of
inflammatory arthritis. He had findings of obstructive
airways disease and decreased diffusion capacity by PFTs,
and HRCT imaging of isolated airways disease (bronchiec-
tasis and air trapping). The second was a 36-year-old man
with an anti-CCP titer of 136 IU and negative RF at the time
of lung evaluation, who developed articular RAw1.5 years
later with an anti-CCP titer of 136 IU and a negative RF. He
had severe airflow limitation on PFTs, and HRCT imaging
evidence of isolated airways disease (bronchiectasis, air
trapping). The third subject developed RA within 0.75
years after her lung evaluation. She was 67 years old and
had an anti-CCP titer of 92 IU and a RF titer of 718 IU at
time of her lung evaluation. She had both obstructive and
restrictive findings on PFTs, and HRCT scan evidence of
airways disease (air trapping) and ILD (ground-glass andTable 3 Subgroup characteristics after stratification by smokin
Age Female
gender
Me
Yea
Never smokers (nZ 31) 66 (20e80) 22 (71%) NA
Smokers (nZ 40 past, 3 active) 70 (41e85) 23 (53%) 18
CPFEZ combined pulmonary fibrosis with emphysema, and ILDZ intreticular opacities in a pattern suggesting an NSIP-pattern
of lung injury).
Discussion
In this study, we characterize the lung phenotype of a novel
cohort of patients that presented with unexplained respi-
ratory symptoms and abnormal thoracic imaging without RA
or other CTD that had a positive anti-CCP antibody on
screening serologic assessment.
The HRCT scan patterns and histopathologic features we
observed were similar to what one would expect to find in
patients with RA-related lung disease,5 thus raising our
suspicion that the lung disease in the subjects in our cohort
may represent a forme fruste of RA e or perhaps a “pre-
arthritis” phenotype in the natural history of RA develop-
ment. Consider our subjects who underwent surgical lung
biopsy; like patients with RA-related ILD, UIP was the most
common interstitial injury pattern. Likewise, in the
majority of airways specimens (and in all specimens from
subjects with ILD), there was lymphoplasmacytic inflam-
mation, a frequent finding in RA-related lung disease.8,15
And finally, as is typically seen in any CTD-related lung
disease, we commonly observed multi-compartment lung
involvement (e.g., airways and parenchymal disease within
the same subject).5,15
We also observed that 3 of 33 subjects (9%) with a high-
titer anti-CCP antibody developed the peripheral synovitis
of RA within 1.5 years of their pulmonary evaluation and
identification of elevated RA-related autoantibodies. The
remaining subjects, despite having a circulating auto-
antibody known to be highly-specific for RA, have not yet
developed RA or other definable CTD.
Recent evidence suggests that protein citrullination,
a process well-known to occur in the lung,16 is a key
component in the pathogenesis of RA. In fact, some inves-
tigators speculate that the immune dysregulation of RAg status.
dian Pack
rs (range)
Isolated
airways
disease
Isolated ILD Airways
disease
and ILD
CPFE
21 (68%) 3 (10%) 7 (23%) 0
(1.3e70) 19 (44%) 7 (16%) 12 (28%) 5 (12%)
erstitial lung disease.
Table 4 Pulmonary function testing after stratification on HRCT pattern.
TLC% RV% FVC% FEV-1% FEV-1/FVC DLCO%
Isolated airways disease (nZ 40) 112 (59e165) 218 (79e340) 75 (45e126) 66 (19e115) 72 74 (37e100)
Isolated ILD (nZ 10) 88 (66e100) 111 (99e166) 72 (46e88) 76 (46e96) 85 43 (25e67)
Airways disease and ILD (nZ 19) 80 (59e142) 145 (84e236) 61 (46e100) 69 (53e105) 84 46 (21e92)
Combined pulmonary fibrosis
with emphysema (nZ 5)
94 (88e98) 104 (90e143) 88 (77e109) 92 (83e112) 76 27 (22e56)
TLCZ total lung capacity, RVZ residual volume, FVCZ forced vital capacity, FEV-1Z forced expiratory volume in 1 s, DLcoZ diffusing
capacity for carbon monoxide, ILDZ interstitial lung disease, and HRCTZ high resolution computed tomography.
Pulmonary physiology data for lung volumes,11 spirometry,13 and diffusing capacity12 based on accepted methodology and performed at
National Jewish Health.
1044 A. Fischer et al.originates in the lungs, not the joints.7,16,17 Cigarette
smoking may play a role: it is a well-established risk factor
for RA and also leads to an increased level of citrullinated
proteins in cells obtained from bronchoalveolar lavage.16
Researchers theorize that once immune dysregulation is
established in the lungs (possibly through protein citrulli-
nation within airway mucosa) a cascade of events ensues.
Depending on an intricate interplay of genetics, environ-
mental exposures, and other factors, potential results
include articular RA with or without clinically apparent RA-
related lung disease.7,16,17 Our observation that 3 subjects
with high-titer anti-CCP antibody levels e all with airways
disease at baseline e had developed the articular mani-
festations of RA by a median 449 days of follow-up would
seem to bolster this theory. Interestingly, only one of these
subjects had ever smoked cigarettes.
Another plausible linkage between the airways and the
development of RA has been put forth by Rangel-Moreno
and colleagues.18 Rangel-Moreno and colleagues showed
that bronchus associated lymphoid tissue (BALT) can be
induced by respiratory infection and is identified in some
patients with pulmonary manifestations of systemicTable 5 Histopathologic findings of bronchoscopic biopsy
specimens after stratification on HRCT pattern.
HRCT pattern Histopathology by bronchial
biopsy
Isolated airways
disease (nZ 4)
Lymphoplasmacytic inflammation
with bronchial inflammation
Lymphoplasmacytic inflammation
(transbronchial)
Granulomata (transbronchial)
Inflammation with eosinophils
Isolated ILD (nZ 2) Cellular bronchiolitis with
granulomata (transbronchial)
Minimal chronic inflammation
Airways disease
and ILD (nZ 4)
Eosinophilic and
lymphoplasmacytic
inflammation
Chronic inflammation
(transbronchial)
Chronic inflammation
Chronic inflammation
HRCTZ high resolution computed tomography, and ILDZ in-
terstitial lung disease.autoimmune diseases, such as RA. Among their subjects,
inducible BALT was associated with the expression of che-
mokines and cytokines involved in the pathology of RA.
Interestingly, and perhaps supportive of a pathologic link,
patients with well-developed BALT exhibited higher levels
of anti-CCP antibodies in BAL fluid. Thus, the authors
conclude that inducible BALT may play a role in the
pulmonary manifestations of RA.18
The clinical implications of a positive anti-CCP in
patients without RA but with lung disease remain to be
determined. It is possible that these patients represent
a pre-RA state and the lung disease reflects a forme fruste
presentation of RA. Recently, Gizinski and colleagues
described four patients with ILD and no articular manifes-
tations of RA, who were RF and anti-CCP positive; all were
male smokers, and within 18 months of follow-up, one had
developed RA.17
The significance of the positive anti-CCP antibody among
subjects in our cohort who have not developed RA is not
known. We believe that there are several distinct possibil-
ities: The first is that these individuals are in a pre-RA state.
They already possess a “RA-related lung disease” pheno-
type, and those with the “right” combination of genetics
and environmental factors will ultimately develop articular
RA. Multiple studies have shown that RA-specific auto-
antibodies may be present years prior to the articular
manifestations of RA, and anti-CCP antibodies are reportedFigure 1 Photomicrograph (10) of histopathology from
transbronchial biopsy demonstrating airways disease with
lymphoplasmacytic inflammation in a subject with anti-CCP
positivity without RA.
Table 6 Histopathologic findings of surgical lung biopsy
specimens after stratification on HRCT pattern.
HRCT pattern Histopathology by surgical lung
biopsy
Isolated airways
disease (nZ 3)
Cellular bronchiolitis with
lymphoplasmacytic inflammation,
organizing pneumonia, increased
perivascular collagen
Organizing pneumonia with
granulomata and fibrosis
Cellular bronchiolitis with
lymphoplasmacytic inflammation
and patchy cellular interstitial
inflammation
Isolated ILD (nZ 4) UIP with lymphoplasmacytic
inflammation, pleuritis,
increased perivascular collagen
UIP with lymphoplasmacytic
inflammation, DIP-like
macrophages
UIP with lymphoplasmacytic
inflammation
DIP with lymphoplasmacytic
inflammation, pleuritis
Airways disease
and ILD (nZ 6)
Bronchiolitis with UIP with
granulomata, lymphoplasmacytic
inflammation, germinal centers,
increased perivascular collagen,
DIP-like macrophages
UIP with lymphoplasmacytic
inflammation, DIP-like macrophages
AIP, with DIP-like macrophages,
lymphoplasmacytic inflammation,
organizing pneumonia
NSIP with lymphoplasmacytic
inflammation
Bronchiolitis and organizing
pneumonia with
lymphoplasmacytic and
eosinophilic inflammation
UIP with lymphoplasmacytic
inflammation, DIP-like
macrophages
Combined
pulmonary
fibrosis with
emphysema
(nZ 1)
UIP with lymphoplasmacytic
inflammation and emphysema
AIPZ acute interstitial pneumonia, DIPZ desquamative inter-
stitial pneumonia, NSIPZ non-specific interstitial pneumonia,
UIPZ usual interstitial pneumonia, and ILDZ interstitial lung
disease.
Figure 2 Photomicrograph (20) of histopathology from
surgical lung biopsy demonstrating UIP with lymphoid aggre-
gates and germinal center formation in a subject with anti-CCP
positivity without RA.
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tion is that anti-CCP generation in our subjects is a non-
specific, non-RA inflammatory response to lung injury.
Indeed, none of the subjects with low-titer or moderate-
titer anti-CCP antibodies have developed the articular
features of RA. Anti-CCP positivity in these subjects may bea false-positive reaction. Such a finding has been described
by Elkayam and colleagues in patients with active pulmo-
nary tuberculosis, with later testing identifying that anti-
CCP reactivity was in reality binding to non-citrullinated
residues on the antigen plate.22 The final, and we believe
least likely, possibility is that the assay used to detect anti-
CCP at our center has a high-degree of false positives. Our
clinical laboratory uses the INOVA Diagnostics QUANTA
Lite CCP3.1 IgG/IgA ELISA kit (San Diego, CA, USA). This
commercially available, third-generation CCP ELISA kit, is
used worldwide, and is reported to be 70% sensitive and 98%
specific for RA.2,21 Because there was a question about
whether the initial anti-CCP result was a “true” positive
(most likely because the subject had no articular manifes-
tations of RA), 15 subjects had a repeat anti-CCP test
performed; 12 of whom had a high-titer positive anti-CCP
on repeat testing. The three that were negative on retest
had initial low-titer anti-CCP. Because repeat testing was
not uniformly performed, and alternative CCP kits were not
used to further confirm antibody positivity, it is possible
that other subjects may have had a false-positive result.
This study has other limitations. The retrospective
design means that data were not systematically collected,
and results should be viewed as hypothesis generating. Only
half of the subjects were evaluated by a rheumatologist, so
it is possible that in the other half of subjects subtle
synovitis or the presence of other subtle extra-thoracic CTD
features may have been missed at the time the anti-CCP
antibody level was determined. We believe that because
we excluded any potential subject who admitted to joint
pain or stiffness on systems review, and because we
excluded any patient with pre-existing diagnoses of RA or
other CTD, we were unlikely to include a large number of
subjects with RA at baseline. The short-term follow-up
limits the potential to draw definite conclusions about the
evolution to RA. Another important limitation of this study
is the lack of a control group. The cohort was formed by
identifying individuals with a positive anti-CCP, without
prior history or current features of RA or other CTD. The
anti-CCP test was ordered by the evaluating clinician as
part of a screening assessment for occult CTD. Obviously,
not every patient with respiratory symptoms at our center
Table 7 Characteristics of subjects who developed articular RA during follow-up.
Subject 1 Subject 2 Subject 3
Age in years 70 36 67
Gender Male Male Female
Smoking history 13 pack years None None
Current smoker No No No
Anti-CCP titer 175 IU 136 IU 92 IU
RF titer 366 IU Negative 718 IU
HRCT pattern Isolated airways
disease
Isolated airways
disease
Airways disease & ILD
Histopathology (TBBx) None Lympho-plasmacytic
inflammation
Lympho-plasmacytic and
eosinophilic inflammation
Time to development of
articular RA
234 days 561 days 261 days
RFZ rheumatoid factor, RAZ rheumatoid arthritis, CCPZ cyclic-citrullinated peptide, IUZ international units, ILDZ interstitial lung
disease, HRCTZ high resolution computed tomography, and TBBxZ transbronchial biopsy.
1046 A. Fischer et al.was tested for anti-CCP antibodies. Thus, although we have
characterized the lung phenotype in this hypothesis-
generating study, additional research is needed to answer
some important questions about anti-CCP antibodies in
patients with respiratory symptoms. Does anti-CCP influ-
ence the pulmonary phenotype? Does it impact on the
natural history of lung disease? How well does it predict
the later development of RA in such patients? Does it lend
support for theories favoring the lungs as the initial site of
RA-associated immune dysregulation?
In conclusion, we have described a cohort of patients
with lung disease and anti-CCP antibody positivity but
without evidence of RA or other CTD. We found that these
subjects have pulmonary phenotypic features that are
similar to those seen in patients with established RA.
Although we do not know whether this autoantibody
impacts the natural history of the lung diseases we identi-
fied, our findings do support the concept that the combi-
nation of elevated anti-CCP antibody levels and lung
disease, in patients without RA, may represent a pre-RA
phenotype, and these patients should be followed for the
development of synovitis. Our results also lend support for
the hypothesis that the lungs may be an initial site of RA-
related immune dysregulation e or of RA itself. Finally, we
believe that prospective study is needed and will help
answer questions about the etiopathogenesis of RA, the
role of protein citrullination in the lungs, and the clinical
impact of anti-CCP positivity on the natural history of
airway and parenchymal lung disease.
Funding
This research was not supported by any grant or other
source of funding.
Author contribution
All of the authors had meaningful contributions on this
research project and manuscript.
Conception and design: AF, JJS, JJS, RMdB, KKB, ALO,
TJH, ERFP, KDD. Analysis and interpretation: AF, RMdB,RJM, DAL, DAB, IRP, SDG, RDDA, JJS, JJS, KDD, KKB, ADS,
MG, AMR. Drafting the manuscript for important intellec-
tual content: AF, RMdB, RJM, JJS, KKB, KDD, JJS, and RJM.
Aryeh Fischer serves as the corresponding author and is
the guarantor of the paper, taking responsibility for the
integrity of the work as a whole, from inception to pub-
lished article.Conflict of interest
None of the authors have any conflicts of interest pertinent
to this research to disclose.Acknowledgements
The authors thank Jennifer Brandorff for her assistance
with the regulatory components of this study.References
1. Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung
diseases in collagen vascular diseases. Eur Respir J Suppl 2001;
32:69se80s.
2. Avouac J, Gossec L, Dougados M. Diagnostic and predictive
value of anti-cyclic citrullinated protein antibodies in rheu-
matoid arthritis: a systematic literature review. Ann Rheum Dis
2006;65(7):845e51.
3. Deane KD, Norris JM, Holers VM. Preclinical rheumatoid
arthritis: identification, evaluation, and future directions for
investigation. Rheum Dis Clin North Am 2010;36(2):213e41.
4. Majka DS, Deane KD, Parrish LA, Lazar AA, Baron AE,
Walker CW, et al. Duration of preclinical rheumatoid arthritis-
related autoantibody positivity increases in subjects with older
age at time of disease diagnosis. Ann Rheum Dis 2008;67(6):
801e7.
5. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007;
4(5):443e8.
6. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K.
Anti-cyclic citrullinated peptide antibodies in lung diseases
associated with rheumatoid arthritis. Clin Biochem 2008;
41(13):1074e7.
Lung disease and anti-CCP antibodies 10477. Aubart F, Crestani B, Nicaise-Roland P, Tubach F, Bollet C,
Dawidowicz K, et al. High levels of anti-cyclic citrullinated
peptide autoantibodies are associated with co-occurrence of
pulmonary diseases with rheumatoid arthritis. J Rheumatol
2011;38(6):979e82.
8. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM.
Connective tissue disease-associated interstitial lung disease:
a call for clarification. Chest 2010;138(2):251e6.
9. Teramoto S, Komiya K, Akashi S, Kawashima M. A clue to
diagnosing connective tissue disease-associated interstitial
lung disease. Chest 2011;139(3):722.
10. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG,
et al. Prognosis of fibrotic interstitial pneumonia: idiopathic
versus collagen vascular disease-related subtypes. Am J Respir
Crit Care Med 2007;175(7):705e11.
11. Cherniak R. Pulmonary function testing. Toronto: W.B. Saun-
ders Co.; 1977.
12. Crapo RO, Jensen RL, Wanger JS. Single-breath carbon
monoxide diffusing capacity. Clin Chest Med 2001;22(4):
637e49.
13. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference
values from a sample of the general U.S. population. Am J
Respir Crit Care Med 1999;159(1):179e87.
14. Cottin V, Cordier JF. The syndrome of combined pulmonary
fibrosis and emphysema. Chest 2009;136(1):1e2.
15. Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the
rheumatic diseases. Semin Respir Crit Care Med 2007;28(4):
369e78.
16. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP,
Zendman AJ, Eklund A, et al. Smoking increasespeptidylarginine deiminase 2 enzyme expression in human
lungs and increases citrullination in BAL cells. Ann Rheum Dis
2008;67(10):1488e92.
17. Gizinski AM, Mascolo M, Loucks JL, Kervitsky A, Meehan RT,
Brown KK, et al. Rheumatoid arthritis (RA)-specific autoanti-
bodies in patients with interstitial lung disease and absence of
clinically apparent articular RA. Clin Rheumatol 2009;28(5):
611e3.
18. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M,
Randall TD. Inducible bronchus-associated lymphoid tissue
(iBALT) in patients with pulmonary complications of rheuma-
toid arthritis. J Clin Invest 2006;116(12):3183e94.
19. Lutteri L, Malaise M, Chapelle JP. Comparison of second- and
third-generation anti-cyclic citrullinated peptide antibodies
assays for detecting rheumatoid arthritis. Clin Chim Acta 2007;
386(1e2):76e81.
20. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G,
Wadell G, Stenlund H, et al. Antibodies against cyclic citrulli-
nated peptide and IgA rheumatoid factor predict the devel-
opment of rheumatoid arthritis. Arthritis Rheum 2003;48(10):
2741e9.
21. van Gaalen FA, Visser H, Huizinga TW. A comparison of the
diagnostic accuracy and prognostic value of the first and
second anti-cyclic citrullinated peptides (CCP1 and CCP2)
autoantibody tests for rheumatoid arthritis. Ann Rheum Dis
2005;64(10):1510e2.
22. Elkayam O, Segal R, Bendayan D, van Uitert R, Onnekink C,
Pruijn GJ. The anti-cyclic citrullinated peptide response in
tuberculosis patients is not citrulline-dependent and sensitive
to treatment. Arthritis Res Ther 2010;12(1):R12.
